Healthcare Cost-Containment Policies and Intensifying Competition from Companies in Other Industries and Competitors in the Same Industry
First written in FY2016. 3 of 4 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2018: 24 of 73 companies on the "Worse" side.
48 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「In the pharmaceutical industry in which our group operates, the first mid-year revision of official drug prices was implemented in April 2021 as part of the policy to restrain medical costs. …The operating environment remains challenging.」
We continue to recognize drug price revisions resulting from policies to restrain medical costs and the challenging industry environment. - FY2021RestatedAnnual report
「If, due to the competitive environment among dispensing pharmacies, we are unable to secure properties that meet our group's site selection criteria because adequate profitability cannot be expected, or if acquired stores fail to generate earnings as planned, this may affect our group's performance.」
The competitive environment among dispensing pharmacies and the ability of acquired stores to generate earnings continue to be described as factors affecting performance in store openings and M&A. - FY2017RestatedAnnual report
「Competition in the dispensing pharmacy industry has intensified, due in part to increased entry by companies from other industries and growing M&A activity by industry peers. Policies aimed at restraining medical costs have also continued to be implemented. The April 2016 revision of drug prices and dispensing fees was particularly stringent, including not only a reduction in the official drug price schedule but also a special provision reducing fees for pharmacy groups handling more than a certain number of prescriptions.」
Intensifying competition and policies to restrain medical costs continue to be described as a challenging external environment. - FY2016First statedAnnual report
「Competition is intensifying due in part to an increase in market entry by companies from other industries and M&A activity by industry peers. In addition, policies aimed at containing healthcare costs continue to be implemented, and the industry is entering a major period of transition.」
While recognizing population aging as a factor supporting market expansion, the company identifies competition and healthcare cost containment as risks in the external environment.